Cassava Sciences Future Growth
Future criteria checks 3/6
Cassava Sciences is forecast to grow earnings and revenue by 104.9% and 149.8% per annum respectively while EPS is expected to grow by 99.6% per annum.
Key information
104.9%
Earnings growth rate
99.6%
EPS growth rate
Pharmaceuticals earnings growth | 20.9% |
Revenue growth rate | 149.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 12 Apr 2024 |
Recent future growth updates
Recent updates
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28Cassava Sciences Stock: Here We Go Again
Dec 21Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
Dec 02Cassava Sciences Gets Underway Putting Simufilam To The Test
Nov 24Cassava Sciences: Data Rules!
Nov 17Cassava Sciences' Hypothesis Raises Doubts
Nov 08Cassava Sciences Stock: Massive Potential Marred By Controversy
Nov 01Cassava Sciences: Welcome To The Casino
Oct 25Has Cassava Sciences Put Out The Fire For Now?
Sep 28Cassava Sciences: Medical History In The Making
Sep 21Cassava Sciences: One Doubtful Drug For One Doubtful Indication
Sep 15We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth
Sep 14More On Cassava Sciences' Controversy
Sep 04Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor
Aug 265 Reasons Cassava Sciences Could Still Be The Most Undervalued Stock In The Market
Jul 27Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 300 | 120 | N/A | N/A | 1 |
12/31/2024 | N/A | -93 | N/A | N/A | 1 |
12/31/2023 | N/A | -97 | -82 | -82 | N/A |
9/30/2023 | N/A | -95 | -81 | -81 | N/A |
6/30/2023 | N/A | -90 | -77 | -76 | N/A |
3/31/2023 | N/A | -83 | -70 | -67 | N/A |
12/31/2022 | N/A | -76 | -80 | -78 | N/A |
9/30/2022 | N/A | -71 | -67 | -64 | N/A |
6/30/2022 | N/A | -61 | -81 | -57 | N/A |
3/31/2022 | N/A | -46 | -74 | -51 | N/A |
12/31/2021 | N/A | -32 | -52 | -30 | N/A |
9/30/2021 | N/A | -21 | -45 | -23 | N/A |
6/30/2021 | N/A | -13 | -11 | -11 | N/A |
3/31/2021 | N/A | -9 | -6 | -6 | N/A |
12/31/2020 | N/A | -6 | -5 | -5 | N/A |
9/30/2020 | N/A | -5 | -5 | -5 | N/A |
6/30/2020 | N/A | -4 | -3 | -3 | N/A |
3/31/2020 | N/A | -4 | -3 | -3 | N/A |
12/31/2019 | N/A | -5 | -3 | -3 | N/A |
9/30/2019 | N/A | -4 | -3 | -2 | N/A |
6/30/2019 | N/A | -4 | -3 | -3 | N/A |
3/31/2019 | N/A | -6 | -4 | -4 | N/A |
12/31/2018 | N/A | -7 | -5 | -5 | N/A |
9/30/2018 | N/A | -8 | -6 | -6 | N/A |
6/30/2018 | N/A | -10 | -6 | -6 | N/A |
3/31/2018 | N/A | -11 | -8 | -8 | N/A |
12/31/2017 | N/A | -12 | -8 | -8 | N/A |
9/30/2017 | N/A | -12 | N/A | -10 | N/A |
6/30/2017 | N/A | -13 | N/A | -10 | N/A |
3/31/2017 | N/A | -12 | N/A | -11 | N/A |
12/31/2016 | N/A | -15 | N/A | -12 | N/A |
9/30/2016 | N/A | -17 | N/A | -13 | N/A |
6/30/2016 | N/A | -17 | N/A | -12 | N/A |
3/31/2016 | N/A | -17 | N/A | -11 | N/A |
12/31/2015 | N/A | -14 | N/A | -9 | N/A |
9/30/2015 | N/A | -12 | N/A | -8 | N/A |
6/30/2015 | N/A | -12 | N/A | -7 | N/A |
3/31/2015 | N/A | -12 | N/A | -8 | N/A |
12/31/2014 | N/A | -12 | N/A | -10 | N/A |
9/30/2014 | 35 | 23 | N/A | -8 | N/A |
6/30/2014 | 37 | 26 | N/A | -9 | N/A |
3/31/2014 | 39 | 29 | N/A | -8 | N/A |
12/31/2013 | 41 | 32 | N/A | -7 | N/A |
9/30/2013 | 8 | -3 | N/A | -7 | N/A |
6/30/2013 | 9 | -4 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SAVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: SAVA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SAVA is expected to become profitable in the next 3 years.
Revenue vs Market: SAVA is forecast to have no revenue next year.
High Growth Revenue: SAVA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SAVA's Return on Equity is forecast to be high in 3 years time